Marshall Wace LLP Has $558,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Marshall Wace LLP lessened its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 32.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,906 shares of the company's stock after selling 24,973 shares during the period. Marshall Wace LLP owned about 0.05% of ARS Pharmaceuticals worth $558,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of ARS Pharmaceuticals by 189.7% during the 3rd quarter. Barclays PLC now owns 111,666 shares of the company's stock valued at $1,618,000 after purchasing an additional 73,127 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of ARS Pharmaceuticals by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company's stock worth $217,000 after buying an additional 1,962 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of ARS Pharmaceuticals by 93.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company's stock valued at $3,631,000 after acquiring an additional 165,950 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of ARS Pharmaceuticals by 2.9% during the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after acquiring an additional 1,824 shares in the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in ARS Pharmaceuticals during the 4th quarter worth $4,469,000. Institutional investors and hedge funds own 68.16% of the company's stock.

ARS Pharmaceuticals Trading Down 1.4 %

SPRY stock traded down $0.19 during midday trading on Thursday, hitting $13.30. The stock had a trading volume of 244,094 shares, compared to its average volume of 1,182,166. The firm has a market cap of $1.31 billion, a P/E ratio of -26.08 and a beta of 0.84. The business has a fifty day moving average price of $13.02 and a two-hundred day moving average price of $13.01. ARS Pharmaceuticals, Inc. has a 1-year low of $7.55 and a 1-year high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. On average, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Insider Activity

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,002 shares of the firm's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,587,255.80. This trade represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 7,696 shares in the company, valued at $107,744. This represents a 56.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,602 shares of company stock worth $1,311,041 in the last quarter. 40.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SPRY shares. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price on the stock. Raymond James upped their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a research report on Tuesday, January 14th. Leerink Partners raised their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Finally, Scotiabank assumed coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.